Facing a complex external environment, WuXi AppTec releases its strongest quarterly report: revenue of 12.4 billion far exceeds expectations.

Against the macro backdrop of a new round of supply shocks and ongoing global economic restructuring, $WuXi AppTec(603259.SH/2359.HK) delivered what can be called the "strongest" Q1 2026 report. The company achieved quarterly revenue of RMB 12.4 billion, not only breaking the RMB 10 billion mark for the first time in Q1 and hitting a new historical high for the same period, but also significantly exceeding market expectations, demonstrating strong risk resistance and growth resilience.

Amid increasing external uncertainties, WuXi AppTec's Q1 revenue achieved a historic breakthrough. Deconstructing the better-than-expected start to the year, its growth engines have undergone a comprehensive upgrade. Not only did its traditionally strong chemical business maintain high growth, but its biology and testing businesses also both delivered impressive double-digit growth. The full-scale breakout of its multi-business matrix not only solidifies its fundamental performance but also sends a clear signal to the global market: WuXi AppTec's unique CRDMO platform is precisely and efficiently capturing the surging demand for global innovative drug R&D with exceptional resilience and breadth.

More noteworthy than the revenue expansion is the continuous optimization of its profit quality. While maintaining high revenue growth, the company achieved a simultaneous enhancement in profitability by continuously optimizing production processes and improving operational efficiency. The overall gross margin remained at an excellent level, fully demonstrating the essence of high-quality growth.

The company's confidence in navigating cycles stems from a solid order foundation. Data shows that as of the end of Q1, WuXi AppTec's backlog of orders for continuing operations had reached as high as RMB 59.8 billion. This substantial order reserve provides high visibility and certainty for the sustained release of future performance.

Facing a complex external environment, WuXi AppTec has effectively responded to market concerns with this "strongest quarterly report." This not only proves the company's ability to effectively withstand external volatility through its global layout, focus on core strategies, and exceptional operational capabilities but also further consolidates its leading position as a core enabler of global pharmaceutical R&D.